T cell engagers control solid tumors through clonal replacement and IL2-driven effector differentiation of CD8 T-cells
Matthias Obenaus, Clara L. Poupault, Christopher S. McGinnis…·K. Christopher García
Combining TCE therapy with IL-2 enhances TCE efficacy in aggressive small-cell lung cancer and melanoma models with low target antigen density through T cell clonal replacement and CD8+ effector T cell differentiation.